Network Pharmacology and Molecular Docking Perspectives into Lignans for Alzheimer's Disease Treatment DOI Open Access
Seda Şirin, Serap Niğdelioğlu Dolanbay

Kahramanmaraş Sütçü İmam Üniversitesi Tarım ve Doğa Dergisi, Год журнала: 2024, Номер unknown

Опубликована: Авг. 14, 2024

Alzheimer’s Disease (AD) is a debilitating neurodegenerative condition with limited treatment options. Lignans, class of naturally occurring polyphenols found in various plants, have been shown to the potential modulate pathways associated AD pathology. In this study, we used network pharmacology and molecular docking investigate therapeutic lignans against by targeting specific proteins involved disease progression. Our established interaction includes key such as EGFR, HSP90AA1, BCL2, HSP90AB1, IL6, JUN, ESR1, PIK3CA, ERBB2, PIK3R1. Molecular studies revealed how interact these highlighted their influence through mechanisms inflammation modulation, apoptosis regulation, signal transduction pathways. The results suggest that significant binding abilities targets, potentially inhibiting activity thus alleviating symptoms reducing amyloid-beta accumulation tau phosphorylation. These findings support viability basis for development new therapies call further vivo confirm efficacy safety. This integrated approach underscores value combining search agents complex diseases AD.

Язык: Английский

Network Pharmacology and Molecular Docking Perspectives into Lignans for Alzheimer's Disease Treatment DOI Open Access
Seda Şirin, Serap Niğdelioğlu Dolanbay

Kahramanmaraş Sütçü İmam Üniversitesi Tarım ve Doğa Dergisi, Год журнала: 2024, Номер unknown

Опубликована: Авг. 14, 2024

Alzheimer’s Disease (AD) is a debilitating neurodegenerative condition with limited treatment options. Lignans, class of naturally occurring polyphenols found in various plants, have been shown to the potential modulate pathways associated AD pathology. In this study, we used network pharmacology and molecular docking investigate therapeutic lignans against by targeting specific proteins involved disease progression. Our established interaction includes key such as EGFR, HSP90AA1, BCL2, HSP90AB1, IL6, JUN, ESR1, PIK3CA, ERBB2, PIK3R1. Molecular studies revealed how interact these highlighted their influence through mechanisms inflammation modulation, apoptosis regulation, signal transduction pathways. The results suggest that significant binding abilities targets, potentially inhibiting activity thus alleviating symptoms reducing amyloid-beta accumulation tau phosphorylation. These findings support viability basis for development new therapies call further vivo confirm efficacy safety. This integrated approach underscores value combining search agents complex diseases AD.

Язык: Английский

Процитировано

0